Literature DB >> 604359

Immune complexes and abnormal liver function in haemophilia.

B A McVerry, J Voke, I Mohammed, K M Dormandy, E J Holborow.   

Abstract

Abnormal 125I-Clq-binding activity was found in the sera of 94% of 55 haemophiliacs. Sera from 66% of these patients inhibited macrophage uptake of labelled aggregated human IgG in a competitive radiobioassay. These results suggest that large molecular weight immune complexes are present in these sera. Analysis of the precipitates obtained directly from the sera by addition of 4% polyethylene glycol showed either a mixture of IgG and IgM or IgM alone. There was poor correlation between the radiobioassay results and the Clq-binding activities in the whole group of 55 patients, suggesting a heterogeneous population of complexes. Nevertheless, a significant correlation was found between Clq-binding activities and the radiobioassay results in seven patients with antibodies to factor VIII, suggesting a homogeneous population of complexes. There was poor correlation between the level of immune complexes and the amount of replacement therapy the patient had received in the previous six months. Abnormal liver function tests were found in 55% of the patients studied but there was poor correlation between these abnormal levels and the Clq binding activities and radiobioassay results. Only two patients had clinical evidence of liver disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 604359      PMCID: PMC476697          DOI: 10.1136/jcp.30.12.1142

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  16 in total

1.  Asymptomatic liver disease in haemophiliacs.

Authors:  P M Mannucci; A Capitanio; E Del Ninno; M Colombo; F Pareti; Z M Ruggeri
Journal:  J Clin Pathol       Date:  1975-08       Impact factor: 3.411

2.  Gamma globulin complexes in rheumatoid arthritis and certain other conditions.

Authors:  H G KUNKEL; H J MULLER-EBERHARD; H H FUDENBERG; T B TOMASI
Journal:  J Clin Invest       Date:  1961-01       Impact factor: 14.808

3.  A method for the study of antihaemophilic globulin inhibitors with reference to six cases.

Authors:  R BIGGS; E BIDWELL
Journal:  Br J Haematol       Date:  1959-10       Impact factor: 6.998

4.  Comprehensive health care clinic for hemophiliacs.

Authors:  P H Levine; B A McVerry; A E Segelman; C M Cranford; S Zimbler
Journal:  Arch Intern Med       Date:  1976-07

5.  Hepatitis-B antigen in saliva and semen.

Authors:  J Heathcote; C H Cameron; D S Dane
Journal:  Lancet       Date:  1974-01-19       Impact factor: 79.321

6.  Immune complexes in hepatitis.

Authors:  J D Almeida; A P Waterson
Journal:  Lancet       Date:  1969-11-08       Impact factor: 79.321

7.  Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom.

Authors:  R Biggs
Journal:  Br J Haematol       Date:  1974-03       Impact factor: 6.998

8.  Circulating conversion products of C3 in liver disease. Evidence for in vivo activation of the complement system.

Authors:  P Teisberg; E Gjone
Journal:  Clin Exp Immunol       Date:  1973-08       Impact factor: 4.330

9.  Effect of penicillamine therapy on circulating immune complexes in rheumatoid arthritis.

Authors:  I Mohammed; D Barraclough; E J Holborow; B M Ansell
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

10.  Serum complement in chronic liver disease.

Authors:  B J Potter; A M Trueman; E A Jones
Journal:  Gut       Date:  1973-06       Impact factor: 23.059

View more
  3 in total

1.  Cryoglobulinaemia in haemophilia.

Authors:  C A Lee; P B Kernoff; D K Peters
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-29

2.  Viral exposure and abnormal liver function in haemophilia.

Authors:  B A McVerry; M G Ross; W A Knowles; J Voke
Journal:  J Clin Pathol       Date:  1979-04       Impact factor: 3.411

3.  Plasma protein variations in hemophiliacs receiving factor replacement therapy.

Authors:  Monica Singh; Puneetpal Singh; Harsurinder Kaur
Journal:  Indian J Pediatr       Date:  2007-05       Impact factor: 5.319

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.